Prognostic Value of a Combination of Circulating Biomarkers in Critically Ill Patients with Traumatic Brain Injury: Results from the European CREACTIVE Study
Restricted accessResearch articleFirst published online October, 2021
Prognostic Value of a Combination of Circulating Biomarkers in Critically Ill Patients with Traumatic Brain Injury: Results from the European CREACTIVE Study
Individualized patient care is essential to reduce the global burden of traumatic brain injury (TBI). This pilot study focused on TBI patients admitted to intensive care units (ICUs) and aimed at identifying patterns of circulating biomarkers associated with the disability level at 6 months from injury, measured by the extended Glasgow Outcome Scale (GOS-E). The concentration of 107 biomarkers, including proteins related to inflammation, innate immunity, TBI, and central nervous system, were quantified in blood samples collected on ICU admission from 80 patients. Patients were randomly selected among those prospectively enrolled in the Collaborative Research on Acute Traumatic Brain Injury in Intensive Care Medicine in Europe (CREACTIVE) observational study. Six biomarkers were selected to be associated with indicators of primary or secondary brain injury: three glial proteins (glial cell–derived neurotrophic factor, glial fibrillary acidic protein, and S100 calcium-binding protein B) and three cytokines (stem cell factor, fibroblast growth factor [FGF] 23 and FGF19). The subjects were grouped into three clusters according to the expression of these proteins. The distribution of the 6-month GOS-E was significantly different across clusters (p < 0.001). In two clusters, the number of 6-month deaths or vegetative states was significantly lower than expected, as calculated according to a customization of the corticosteroid randomization after significant head injury (CRASH) scores (observed/expected [O/E] events = 0.00, 95% confidence interval [CI]: 0.00-0.90 and 0.00, 95% CI: 0.00-0.94). In one cluster, less-than-expected unfavorable outcomes (O/E = 0.50, 95% CI: 0.05-0.95) and more-than-expected good recoveries (O/E = 1.55, 95% CI: 1.05-2.06) were observed. The improved prognostic accuracy of the pattern of these six circulating biomarkers at ICU admission upon established clinical parameters and computed tomography results needs validation in larger, independent cohorts. Nonetheless, the results of this pilot study are promising and will prompt further research in personalized medicine for TBI patients.
WangK.K., YangZ., ZhuT., ShiY., RubensteinR., TyndallJ.A., and ManleyG.T. (2018). An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev. Mol. Diagn. 18, 165–180.
5.
FrankelM., FanL., YeattsS.D., JerominA., VosP.E., WagnerA.K., WolfB.J., PaulsQ., LunneyM., MerckL.H., HallC.L., PaleschY.Y., SilbergleitR., and WrightD.W. (2019). Association of very early serum levels of S100B, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and spectrin breakdown product with outcome in ProTECT III. J. Neurotrauma, 36, 2863–2871.
6.
ZetterbergH., SmithD.H., and BlennowK. (2013). Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat. Rev. Neurol. 9, 201–210.
7.
ThelinE., Al NimerF., FrostellA., ZetterbergH., BlennowK., NyströmH., SvenssonM., BellanderB.-M., PiehlF., and NelsonD.W. (2019). A serum protein biomarker panel improves outcome prediction in human traumatic brain injury. J. Neurotrauma, 36, 2850–2862.
8.
TakalaR.S.K., PostiJ.P., RunttiH., NewcombeV.F., OuttrimJ., KatilaA.J., FrantzénJ., Ala-SeppäläH., KyllönenA., MaanpääH.-R., TallusJ., HossainM.I., ColesJ.P., HutchinsonP., van GilsM., MenonD.K., and TenovuoO. (2016). Glial Fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 87, 8–20.
9.
CzeiterE., MondelloS., KovacsN., SandorJ., GabrielliA., SchmidK., TortellaF., WangK.K.W., HayesR.L., BarzoP., EzerE., DocziT., and BukiA. (2012). Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J. Neurotrauma, 29, 1770–1778.
10.
Diaz-ArrastiaR., WangK.K.W., PapaL., SoraniM.D., YueJ.K., PuccioA.M., McMahonP.J., InoueT., YuhE.L., LingsmaH.F., MaasA.I.R., ValadkaA.B., OkonkwoD.O., ManleyG.T., CaseyS.S., CheongM., CooperS.R., Dams-O'ConnorK., GordonW.A., HricikA.J., MenonD.K., MukherjeeP., SchnyerD.M., SinhaT.K., and VassarM.J. (2014). Acute biomarkers of traumatic brain injury: relationship between plasma levels of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein. J. Neurotrauma, 31, 19–25.
11.
HuieJ.R., Diaz-ArrastiaR., YueJ.K., SoraniM.D., PuccioA.M., OkonkwoD.O., ManleyG.T., and FergusonA.R.; TRACK-TBIInvestigators. (2019). Testing a multivariate proteomic panel for traumatic brain injury biomarker discovery: a TRACK-TBI Pilot Study. J. Neurotrauma, 36, 100–110.
12.
MurrayG.D., ButcherI., McHughG.S., LuJ., MushkudianiN.A., MaasA.I.R., MarmarouA., and SteyerbergE.W. (2007). Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J. Neurotrauma, 24, 329–337.
13.
LingsmaH.F., RoozenbeekB., SteyerbergE.W., MurrayG.D., and MaasA.I.R. (2010). Early prognosis in traumatic brain injury: from prophecies to predictions. Lancet Neurol. 9, 543–554.
14.
CREACTIVE—Welcome to the CREACTIVE project. http://creactive.marionegri.it (Last accessed October2, 2020).
15.
TeasdaleG. and JennettB. (1974). Assessment of coma and impaired consciousness: A Practical Scale. Lancet, 304, 81–84.
16.
WildeE.A., WhiteneckG.G., BognerJ., BushnikT., CifuD.X., DikmenS., FrenchL., GiacinoJ.T., HartT., MalecJ.F., MillisS.R., NovackT.A., ShererM., TulskyD.S., VanderploegR.D., and SteinbuechelN. von. (2010). Recommendations for the use of common outcome measures in traumatic brain injury research. Arch. Phys. Med.Rehabil. 91, 1650–1660.e17.
17.
Brain TraumaFoundation, American Association of NeurologicalSurgeons, Congress of NeurologicalSurgeons, Joint Section on Neurotrauma and Critical CareAANS/CNS, BrattonS.L., ChestnutR.M., GhajarJ., McConnell HammondF.F., HarrisO.A., HartlR., ManleyG.T., NemecekA., NewellD.W., RosenthalG., SchoutenJ., ShutterL., TimmonsS.D., UllmanJ.S., VidettaW., WilbergerJ.E., and WrightD.W. (2007). Guidelines for the management of severe traumatic brain injury. VIII. Intracranial pressure thresholds. J. Neurotrauma 24 Suppl, 1, S55–S58.
18.
JennettB., SnoekJ., BondM.R., and BrooksN. (1981). Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J. Neurol. Neurosurg. Psychiatry, 44, 285–293.
19.
SteyerbergE.W., MushkudianiN., PerelP., ButcherI., LuJ., McHughG.S., MurrayG.D., MarmarouA., RobertsI., HabbemaJ.D.F., and MaasA.I.R. (2008). Predicting outcome after traumatic brain injury: development and international validation of prognostic scores Based on admission characteristics. PLOS Med. 5, e165.
20.
TibshiraniR. (1996). Regression shrinkage and selection via the Lasso. J. Royal Stat. Soc. Series B (Methodol.) 58, 267–288.
21.
WardJ.J.Jr, (1963). Hierarchical grouping to optimize an objective function. J. Am. Stat. Assoc. 58, 236–244.
22.
HosmerD.W. and LemeshowS. (1995). Confidence interval estimates of an index of quality performance based on logistic regression models. Stat. Med. 14, 2161–2172.
23.
HastieT., TibshiraniR., and FriedmanJ. (2009). The Elements of Statistical Learning: Data Mining, Inference, and Prediction, Second Edition. Springer-Verlag: New York.
24.
RichterS., StevensonS., NewmanT., WilsonL., MenonD.K., MaasA.I.R., NieboerD., LingsmaH., SteyerbergE.W., and NewcombeV.F.J. (2019). Handling of missing outcome data in traumatic brain injury research: a systematic review. J. Neurotrauma, 36, 2743–2752.
25.
MadathilS.K. and SaatmanK.E. (2015). IGF-1/IGF-R signaling in traumatic brain injury: impact on cell survival, neurogenesis, and behavioral outcome, in: Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. F.H. Kobeissy, (ed). CRC Press/Taylor and Francis: Boca Raton,FL.
26.
QiuX., PingS., KyleM., ChinL., and ZhaoL.-R. (2021). SCF + G-CSF treatment in the chronic phase of severe TBI enhances axonal sprouting in the spinal cord and synaptic pruning in the hippocampus. Acta Neuropathol. 9, 63.
27.
CzeiterE., AmreinK., GravesteijnB.Y., LeckyF., MenonD.K., MondelloS., NewcombeV., RichterS., SteyerbergE.W., VyvereT.V., VerheydenJ., XuH., YangZ., MaasA.I., WangK.K., and BükiA.; CENTER-TBI Participants andInvestigators. (2020). Blood biomarkers on admission in acute traumatic brain injury: relations to severity, CT findings and care path in the CENTER-TBI study.
28.
OlivecronaZ., BobinskiL., and KoskinenL.-O.D. (2015). Association of ICP, CPP, CT findings and S-100B and NSE in severe traumatic head injury. Prognostic value of the biomarkers. Brain Inj. 29, 446–454.
29.
ThelinE.P., NelsonD.W., and BellanderB.-M. (2017). A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury. Acta Neurochir. (Wien) 159, 209–225.
VoormolenD.C., CnossenM.C., PolinderS., von SteinbuechelN., VosP.E., and HaagsmaJ.A. (2018). Divergent classification methods of post-concussion syndrome after mild traumatic brain injury: prevalence rates, risk factors, and functional outcome. J. Neurotrauma, 35, 1233–1241.
32.
PirracchioR., YueJ.K., ManleyG.T., van der LaanM.J., and HubbardA.E. (2018). Collaborative targeted maximum likelihood estimation for variable importance measure: illustration for functional outcome prediction in mild traumatic brain injuries. Stat. Methods Med. Res. 27, 286–297.
33.
Duarte AzevedoM., SanderS., and TenenbaumL. (2020). GDNF, A neuron-derived factor upregulated in glial cells during disease. J. Clin. Med. 9, 456.
34.
MarksteinerJ., KemmlerG., WeissE., KnausG., UllrichC., MechtcheriakovS., OberbauerH., AuffingerS., HinterhölzlJ., HinterhuberH., and HumpelC. (2009). Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging, 32, 539–540.
35.
TalebiM., MajdiA., NasiriE., NaseriA., and Sadigh-EteghadS. (2020). The correlation between circulating inflammatory, oxidative stress, and neurotrophic factors level with the cognitive outcomes in multiple sclerosis patients. Neurol. Sci. 42, 2291–2300.
36.
ZamperoniA., RossiC., FinazziS., Del SartoP., MondiniM., NattinoG., PooleD., BertoliniG., and Cardiac surgical intensive care writing committee (GiViTI). (2020). Case-mix affects calibration of cardiosurgical severity scores. Minerva Anestesiol. 86, 719–726.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
